Skip to main content
Sunovion logo
  • Health Care Professionals
  • Patients
  • Media
  • Contact Us
  • Sumitomo Dainippon Pharma
  • ENGLISH
    US
    ENGLISH
    EUROPE
    ENGLISH
    CANADA
    ENGLISH FRENCH
    GLOBAL
    ENGLISH
  • Who We Are
    • Who We are overview
    • Our Mission, Vision & Values
    • Executive Leadership
      • Nobuhiko Tamura
      • Greg Bokar
      • Matthew D'Ambrosio
      • David Frawley
      • Stephen Freeman
      • Robert Gregorio
      • Antony Loebel
    • Our History
    • Our People
      • Jeffrey Akin
      • Robin Cruz
      • John Gallo
      • Katrina Iserman
      • Henry McMillan
      • Daniel Yi
    Person photo

    Our employees strive to make a difference in people’s lives

    Meet the people of Sunovion
    Lab photo

    See what we're working on

    Learn more about our Pipeline
    Paper photo

    Get our latest news

    View our Press Releases
  • Join Us
    • Join us overview
    • Benefits
    • Job Search
    • Special Programs
    • General Warning to Job Seekers
    Chart photo

    Our career paths offer you opportunities

    See where your career can take you at Sunovion
    Person photo

    About Sunovion

    Who We Are
    Scientists photo

    Career Opportunities

    Learn more about our career opportunities
  • Responsibility
    • Responsibility overview
    • Patient Support & Advocacy
    • Community Building
    Working man photo

    Responsibility

    Hands On! Day
    Person photo

    About Sunovion

    Who We Are
    Scientists photo

    Career Opportunities

    Learn more about our career opportunities
  • Our Therapies
    • OUR THERAPIES OVERVIEW
    • Aptiom® (eslicarbazepine acetate) tablets
    • Brovana® (aformoterol tartrate) Inhalation Solution
    • KYNMOBITM (apomorphine HCl) sublingual film
    • Latuda® (lurasidone HCi) tablets
    • Lonhala® Magnair® (glycopyrrolate) Inhalation Solution
    • Lunesta® (eszopiclone) tablets
    • Xopenex® HFA (levalbuterol tartrate) Inhalation Aerosol
    Family photo

    Our Therapies

    Find out more about our medications today
    Lab photo

    Pipeline

    Learn more about our treatments for
    tomorrow
    Therapies photo

    CNS Overview

    See how we're treating neurological disorders
  • Research & Development
    • Research & Development overview
    • Our Pipeline
    • Psychiatric Disorders Overview
    • Neurological Disorders Overview
    • Respiratory Disorders Overview
    • Research Grants
    • Disclosure of Clinical Study Data
    Family photo

    Condition Focus

    Bipolar Disorder
    Anthony Loebel photo

    Meet Our Leaders

    Antony Loebel, MD, President and Chief Executive Officer
    Scientist photo

    Research Grants

    Independent Medical Research Grants
  • Explore Partnerships
    • Explore Partnerships Overview
    • Our Partners
    • Partnering Contact Form
    Scientists photo

    Our Approach to Partnership

    See how we're collaborating with partners
    Scientists photo

    Our Partners

    See where we're developing advanced medical therapies
    Scientist photo

    How We Create Value

    Explore the types of partnerships we're looking for
  • Featured News
    Person photo

    Our employees strive to make a difference in people’s lives

    Meet the people of Sunovion
    Notebook photo

    Sunovion Fast Facts

    Media Kit
    Person photo

    About Sunovion

    Who We Are
Sunovion logo
  • Featured News Overview
    • Press Releases

Media Kit

ENGLISH
US
ENGLISH
EUROPE
ENGLISH
CANADA
ENGLISH FRENCH
GLOBAL
ENGLISH
  • Home
  • Who We Are
    • Who We are overview
    • Our Mission, Vision & Values
    • Executive Leadership
      • Nobuhiko Tamura
      • Greg Bokar
      • Matthew D'Ambrosio
      • David Frawley
      • Stephen Freeman
      • Robert Gregorio
      • Antony Loebel
    • Our History
    • Our People
      • Jeffrey Akin
      • Robin Cruz
      • John Gallo
      • Katrina Iserman
      • Henry McMillan
      • Daniel Yi
  • Join Us
    • Join us overview
    • Benefits
    • Job Search
    • Special Programs
    • General Warning to Job Seekers
  • Responsibility
    • Responsibility overview
    • Patient Support & Advocacy
    • Community Building
  • Our Therapies
    • Oor Therapies Overview
    • Aptiom® (eslicarbazepine acetate) tablets
    • Brovana® (aformoterol tartrate) Inhalation Solution
    • Latuda® (lurasidone HCi) tablets
    • Lonhala® Magnair® (glycopyrrolate) Inhalation Solution
    • Lunesta® (eszopiclone) tablets
    • Xopenex® HFA (levalbuterol tartrate) Inhalation Aerosol
  • Research & Development
    • Research & Development overview
    • Our Pipeline
    • Psychiatric Disorders Overview
    • Neurological Disorders Overview
    • Respiratory Disorders Overview
    • Research Grants
    • Disclosure of Clinical Study Data
  • Explore Partnerships
    • Explore Partnerships Overview
    • Our Partners
    • Partnering Contact Form
  • Featured News
  • Health Care Professionals
  • Our Patients
  • Media
  • Contact Us

Follow us on:

  • Featured News Overview
    • Press Releases

Media

Sunovion Media Kit

Fast Facts

Global Headquarters: Marlborough, Massachusetts, USA

Global locations: Sunovion Pharmaceuticals Inc., located in Fort Lee, New Jersey, Sunovion Pharmaceuticals Europe Ltd., based in London, England and Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.

Ownership: Indirectly, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

Core Therapeutic Areas: Address serious psychiatry, neurology, and respiratory conditions

About Sunovion

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s web sites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
© 2019 Sunovion Pharmaceuticals Inc. All rights reserved.

aptiom logo
brovana logo
kynmobi logo
latuda logo
lonhala logo

Pipeline

View our clinical development pipeline.

/files/images/media_kit/2020/KYNMOBI_Logo_Opt1[2].jpg

Image Library

Sunovion Logos

Sunovion Executive Leaders

Meet the Executive Leadership Team

Product Logos

Media Inquiries

Tel: 508-357-7740

Email: corpcomm@sunovion.com

  • Health Care Professionals
  • Patients
  • Media
  • Corporate Documents
  • Join Us
  • Sunovion Parent Company:
    Sumitomo Dainippon Pharma

FOLLOW US ON:

  • Terms of Use
  • Privacy Policy and Cookie Notice
  • Medical Disclaimer
  • Sources

SUNOVION and Sunovion logo are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

LUNESTA, Lunesta logo, XOPENEX HFA, and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc.

APTIOM is a registered trademark of Bial logo, used under license. LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

LONHALA is a registered trademark and Lonhala logo is a trademark of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license.

eFlow and eLete are registered trademarks of PARI Pharma GmbH.

KYNMOBI and Sunovion logo are trademarks of Sunovion Pharmaceuticals Inc.

Powered By Q4 Inc. 5.56.0.1 (opens in new window)